USFDA Flags Issues at Biocon's Andhra Pradesh Plant

The US Food and Drug Administration (USFDA) has made four observations after inspecting Biocon's manufacturing plant in Andhra Pradesh. The inspection concluded on June 21, 2024, with Biocon promising to address the observations within the stipulated time. Violations were cited under the Food Drug and Cosmetic Act.

The US Food and Drug Administration (USFDA) has identified four significant issues during its recent inspection of Biocon's manufacturing plant in Andhra Pradesh. The inspection, completed on June 21, 2024, at the company's API facility (Site 5) in Visakhapatnam, revealed potential violations of the Food Drug and Cosmetic (FD&C) Act.

Biocon has acknowledged the observations and committed to addressing the concerns within the stipulated timeframe. The USFDA issues a Form 483 to a firm's management outlining observed conditions that may constitute non-compliance with regulatory requirements.

This development is critical for Biocon, as it impacts the company's compliance status and adherence to Good Manufacturing Practice (GMP) regulations, pivotal for maintaining product quality and safety standards in the biotechnology sector.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)